EMA Authorised: Tepmetko (tepotinib hydrochloride monohydrate) — Merck Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Tepmetko (tepotinib hydrochloride monohydrate) for use in non-small cell lung cancer, with Merck Europe B.V. as the mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tepmetko (tepotinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Merck Europe B.V.. Decision date: 17/04/2026